This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Advancing today’s therapies to enable healthier lives
We are focused on transforming patient care by enhancing existing therapeutic medicines to bring safer, more effective and convenient treatments to patients
Arecor Proprietary Pipeline
Using our Arestat™ technology platform, we are developing enhanced medicines for the treatment of diabetes and other chronic conditions
Tetris Pharma Portfolio
Our specialty pharmaceutical experts in registering, marketing, sales and the distribution of commercial-stage speciality hospital products across the UK and Europe
Our Partners
We partner with leading pharmaceutical and biotechnology companies through technology partnerships to enhance their proprietary products across a range of indications and stages of development
Latest News and Events
-
30th January 2023
ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE
-
12th January 2023
ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA
-
22nd November 2022
ARECOR TO COMMENCE SECOND CLINICAL TRIAL WITH AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR TYPE 2 DIABETES